Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Intravenous Brincidofovir in Adenovirus or Cytomegalovirus Infection
NCT04706923Phase 2Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- May 2025
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of brincidofovir in adenovirus infection, cytomegalovirus infection (CMV), sponsored by SymBio Pharmaceuticals. Started Aug 2021; status: completed.
02
Drugs
brincidofovir
03
Conditions
adenovirus infectioncytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04706923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706923.